interferon alpha + interferon beta

interferon alpha + interferon beta is an investigational combination therapy consisting of both type I interferons, *interferon alpha* and *interferon beta*. Both interferons are cytokines with antiviral, immunomodulating, and antiproliferative activity. The combination has been studied primarily for enhancing the antiviral response, especially in chronic hepatitis C, by targeting multiple pathways of the innate immune system and maximizing antiviral and immunoregulatory effects. Monotherapies of either interferon alpha or interferon beta are separately indicated for several conditions—chronic hepatitis C (alpha) and multiple sclerosis (beta)—but the combined use is investigational and not an established, broadly approved pharmaceutical product. Typically, combination therapy employs natural interferon beta followed by natural interferon alpha, aiming to improve sustained virological response rates in challenging patient populations[2][7].

Other names

IFN-alpha + IFN-betainterferon alfa + interferon betaIFN-α + IFN-βhuman interferon alpha + interferon betanatural interferon alpha + beta